Gastric Inflammatory Myofibroblastic Tumor in a 10-Year-Old Patient in Macao—Case Report and Literature Review

Abstract

Inflammatory myofibroblastic tumor (IMT) is a special type of mesenchymal tumors. The tumors can occur all over the body. The most common organs involved were lung, followed by mesentery, omentum, retroperitoneum, and pelvic cavity. But it occurs very rarely in the stomach. This article mainly reports a 10-year-old patient who complained of progressive dysphagia for 4 years. Esophagogram suggests esophageal achalasia. Abdominal CT examination revealed a huge mass with calcification in the cardiac region of stomach with metastatic lymphadenopathy. PET-CT was also performed that consistent with malignant gastric tumor with metastatic lymphadenopathy. Gastroscopy also indicated that there was a huge mass in the cardia that compressed the esophagus, and biopsy was performed to reveal chronic gastritis. Pathological analysis was performed after surgical exploration and tissue samples were taken out and the final pathology was consistent with inflammatory myofibroblastic tumors. The patient was not able to undergo surgical treatment, so crizotinib chemotherapy was used. After treatment, the patient's tumors were significantly reduced, and the effect was obvious. The patient is now in stable condition and continues to follow up. This article hopes to review the literature of imaging diagnosis of inflammatory myofibroblastic tumors through this case report, so as to improve the understanding of this disease.

Ileal inflammatory pseudotumor in adolescent male patient with prior Burkitt lymphoma: A challenging diagnosis

“…Inflammatory pseudotumor have a long clinical course, ranging from weeks to several months with benign prognosis in most of the case, and a complete surgical excision is the mainstay of treatment, providing the best chance to limit recurrence. When surgery is not possible, good response can be obtained with chemotherapy and radiotherapy, although there is a lack of validated criteria and guidelines for diagnosis and management of this rare disease [5] , [6] , [7] .…”